streptokinase
Trade name: streptase
Approved
Oct 15, 1977
Streptokinase is a thrombolytic medication activating plasminogen by nonenzymatic mechanism. As a medication it is used to break down clots in some cases of myocardial infarction, pulmonary embolism, and arterial thromboembolism. The type of heart attack it is used in is an ST elevation myocardial infarction (STEMI). It is given by injection into a vein. — Wikipedia
Clinical trial activity
16 trials · 27 clinical orgs · 1 marketing orgs
Earliest trial started Aug 1, 1982 (NCT00000503)
Timeline
1970s
- Jun 1, 1977
Hoechst Marion Roussel — First NDA Organization
- Jun 1, 1977
Hoechst Marion Roussel — NDA Organization
- Oct 15, 1977
Earliest FDA Approval
1980s
- Jan 1, 1982
Earliest Phase 3 Sponsor(trial)
2010s
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Studied for
- Acute Coronary Syndrome · Phase 4
- Bronchitis · Phase 4
- Cardiovascular Diseases · Phase 3
- Coronary Disease · Phase 3
- Heart Diseases · Phase 3
- Ischemic Stroke · Phase 2
- Myocardial Infarction · Phase 4
- Myocardial Ischemia · Phase 3
- Pancreatitis · Phase 2/Phase 3
- Pulmonary Embolism · Phase 4
- Reperfusion Injury · Phase 4
- Respiratory Distress Syndrome · Phase 3
- Respiratory Tract Infections · Phase 4
- Severe Acute Respiratory Syndrome · Phase 3
- Thrombosis · Phase 3
Mechanism of action
- PlasminogenACTIVATOR
PLG activator
Approval history
- approvedOct 15, 1977
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaStreptokinase ↗
- NCATSL5IJH7302K ↗
- ChEMBLCHEMBL2108147 ↗
Also known as
- kabikinase
- kabikinase
- streptase
- streptase
- streptase
- streptokinase
- streptokinase
- streptokinase
- streptokinase
- streptokinase
- streptokinase
- streptokinase c precursor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04252963 | Phase 4 | Nov 2, 2018 | Hanmi Pharmaceutical, Konkuk University |
| NCT03595085 | N/A | Sep 1, 2018 | Assiut University |
| NCT01641549 | Phase 3 | Apr 1, 2017 | All India Institute of Medical Sciences |
| NCT03465085 | Phase 3 | Feb 18, 2016 | Beni Suef University |
| NCT02150785 | Phase 2 | Jun 1, 2014 | University of Alberta |
| NCT01977118 | Phase 2/Phase 3 (Phase 3) | May 1, 2013 | Postgraduate Institute of Medical Education and Research |
| NCT01305226 | Phase 3 | Oct 1, 2010 | Bharat Biotech International Limited |
| NCT00627809 | Phase 4 | Jan 1, 2007 | Istanbul University |
| NCT00968929 | Phase 4 | Jun 1, 2006 | Capital Medical University, Guangzhou Medical University, Ningxia Medical University, People's Liberation Army of China, Qingdao University, Shanxi Medical University, Shenzhen University, Tianjin Medical University |
| NCT00232622 | Phase 3 | Nov 1, 2004 | All India Institute of Medical Sciences |
| NCT00302419 | Phase 4 | Oct 1, 2004 | Istanbul University |
| NCT00245648 | Phase 3 | Jun 1, 2001 | Centocor, Eli Lilly, New York University, University of Rochester |
| NCT02182011 | Phase 3 | May 1, 2000 | Boehringer Ingelheim |
| NCT01451320 | N/A | Jan 1, 1993 | Kosuyolu Heart Hospital, Yuksek Ihtisas University |
| NCT00000507 | Phase 3 | Aug 1, 1983 | National Heart, Lung, and Blood Institute (NHLBI), University of Washington |
| NCT00000503 | Phase 3 | Aug 1, 1982 | Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI) |
Organizations
Research & Development (27)
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Hoechst Marion Roussel | For profit | NDA | Jun 1, 1977 |